{
    "clinical_study": {
        "@rank": "134521", 
        "arm_group": {
            "arm_group_label": "MEDI-551", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the safety and tolerability of MEDI-551\n      in Japanese patients with relapsed or refractory advanced B-cell malignancies."
        }, 
        "brief_title": "A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Blood Cancer", 
            "Advanced B Cell Malignancies"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Hematologic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Japanese men or women at least 20 years of age\n\n          -  Histologically confirmed CLL (excluding small lymphocytic lymphoma (SLL)), DLBCL, FL,\n             or MM.\n\n          -  Karnofsky Performance Status \u226570;\n\n          -  Life expectancy of \u226512 weeks\n\n        Exclusion Criteria:\n\n          -  Any available standard line of therapy known to be life-prolonging or life-saving\n\n          -  Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal\n             therapy for treatment of cancer\n\n          -  Previous therapy directed against CD19, such as monoclonal antibodies or MAb\n             conjugates"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT01377116", 
            "nct_id": "NCT01957579", 
            "org_study_id": "D2850C00001"
        }, 
        "intervention": {
            "arm_group_label": "MEDI-551", 
            "description": "MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle", 
            "intervention_name": "MEDI-551", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Phase I", 
            "advanced", 
            "B cell malignancies", 
            "dose escalation", 
            "CD19", 
            "Japanese"
        ], 
        "lastchanged_date": "April 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Nagoya-shi", 
                        "country": "Japan", 
                        "state": "Aichi"
                    }, 
                    "name": "Research site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Isehara", 
                        "country": "Japan", 
                        "state": "Kanagawa"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Isehara-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagoya-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies", 
        "overall_official": {
            "affiliation": "MedImmune LLC", 
            "last_name": "Trishna Goswami", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Ministry of Health, Labor and Welfare", 
                "Japan: Pharmaceuticals and Medical Devices Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Patients with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to 30 days after the last dose of study drug"
            }, 
            {
                "measure": "Change from Baseline to 30days after the last ndose of MEDI-551 in laboratory data, vital signs, and ECG", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to 30 days after the last dose of study drug"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01957579"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To characterize the drug concentrations in serum and effect on circulating lymphocyte populations and Ig levels", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 3 months after the last dose of study drug"
            }, 
            {
                "measure": "Immunogenicity of MEDI-551 by measuring anti-MEDI-551 antibodies", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 3 months after the last dose of study drug"
            }, 
            {
                "measure": "Anti-tumor activity of MEDI-551 using Complete Response Rate", 
                "safety_issue": "No", 
                "time_frame": "From the baseline to30 days after the last dose of study drug"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "collaborator": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}